口服免疫疗法失败应被视为致命性过敏性休克的风险因素，并考虑奥马珠单抗治疗。

IF 3.2 3区医学 Q1 PEDIATRICS Italian Journal of Pediatrics Pub Date : 2024-11-09 DOI:10.1186/s13052-024-01814-7

Francesca Nicolardi, Federica Corona, Laura Badina, Irene Berti, Egidio Barbi

{"title":"口服免疫疗法失败应被视为致命性过敏性休克的风险因素，并考虑奥马珠单抗治疗。","authors":"Francesca Nicolardi, Federica Corona, Laura Badina, Irene Berti, Egidio Barbi","doi":"10.1186/s13052-024-01814-7","DOIUrl":null,"url":null,"abstract":"Oral immunotherapy is proposed as the only active intervention to modify allergies and decrease the risk of severe reactions. However, it is crucial to note that oral immunotherapy still presents a notable failure rate and potential for severe, life-threatening outcomes. Notably, patients who discontinue oral immunotherapy may face an increased risk of fatal reactions. Omalizumab could be a viable option for patients with failed oral immunotherapy.","PeriodicalId":14511,"journal":{"name":"Italian Journal of Pediatrics","volume":"50 1","pages":"232"},"PeriodicalIF":3.2000,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549735/pdf/","citationCount":"0","resultStr":"{\"title\":\"Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered.\",\"authors\":\"Francesca Nicolardi, Federica Corona, Laura Badina, Irene Berti, Egidio Barbi\",\"doi\":\"10.1186/s13052-024-01814-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Oral immunotherapy is proposed as the only active intervention to modify allergies and decrease the risk of severe reactions. However, it is crucial to note that oral immunotherapy still presents a notable failure rate and potential for severe, life-threatening outcomes. Notably, patients who discontinue oral immunotherapy may face an increased risk of fatal reactions. Omalizumab could be a viable option for patients with failed oral immunotherapy.\",\"PeriodicalId\":14511,\"journal\":{\"name\":\"Italian Journal of Pediatrics\",\"volume\":\"50 1\",\"pages\":\"232\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-11-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549735/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Italian Journal of Pediatrics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13052-024-01814-7\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Italian Journal of Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13052-024-01814-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

摘要

口服免疫疗法被认为是改变过敏症状和降低严重反应风险的唯一积极干预措施。然而，必须指出的是，口服免疫疗法仍然存在明显的失败率，并有可能导致严重的、危及生命的后果。值得注意的是，中断口服免疫疗法的患者可能会面临更高的致命反应风险。对于口服免疫疗法失败的患者来说，奥马珠单抗可能是一种可行的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered.

Oral immunotherapy is proposed as the only active intervention to modify allergies and decrease the risk of severe reactions. However, it is crucial to note that oral immunotherapy still presents a notable failure rate and potential for severe, life-threatening outcomes. Notably, patients who discontinue oral immunotherapy may face an increased risk of fatal reactions. Omalizumab could be a viable option for patients with failed oral immunotherapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Italian Journal of Pediatrics PEDIATRICS-

CiteScore

6.10

自引率

13.90%

发文量

192

审稿时长

6-12 weeks

期刊介绍： Italian Journal of Pediatrics is an open access peer-reviewed journal that includes all aspects of pediatric medicine. The journal also covers health service and public health research that addresses primary care issues. The journal provides a high-quality forum for pediatricians and other healthcare professionals to report and discuss up-to-the-minute research and expert reviews in the field of pediatric medicine. The journal will continue to develop the range of articles published to enable this invaluable resource to stay at the forefront of the field. Italian Journal of Pediatrics, which commenced in 1975 as Rivista Italiana di Pediatria, provides a high-quality forum for pediatricians and other healthcare professionals to report and discuss up-to-the-minute research and expert reviews in the field of pediatric medicine. The journal will continue to develop the range of articles published to enable this invaluable resource to stay at the forefront of the field.